文献速递胃肠外科

确定可切除非贲门胃癌患者的最佳治疗策略

Identifying the optimal treatment strategy in patients with resectable non-cardia gastric cancer.
PubMed 文献 · Surg Endosc · 2023-11-07

基于美国国家癌症数据库2006至2016年9589例可切除非贲门胃癌患者,比较围手术期化疗、术后放化疗与术后化疗的生存差异。围手术期化疗和术后放化疗较术后化疗均与生存改善相关,两者间无显著差异,最佳治疗亚组结果一致。

要点

  • 围手术期化疗组中位生存60.6个月,术后放化疗组42.3个月,术后化疗组31.2个月。
  • 与术后化疗相比,围手术期化疗和术后放化疗均与生存改善相关(HR 0.78和0.79;p < 0.001)。
  • 围手术期化疗与术后放化疗之间无显著差异(HR 1.01;p = 0.987)。

核心结论

  • 在可切除非贲门胃癌患者中,围手术期化疗和术后放化疗较术后化疗均与生存改善相关,围手术期化疗与术后放化疗之间无差异,最佳治疗亚组结果一致。

研究设计与样本

  • 回顾性分析美国国家癌症数据库2006至2016年数据,纳入9589例可切除非贲门胃癌患者,按接受围手术期化疗、术后放化疗或术后化疗分组比较结局,并在最佳治疗亚组(n = 3418)中重复比较。

主要发现

  • 围手术期化疗组中位生存60.6个月,术后放化疗组42.3个月,术后化疗组31.2个月。
  • 多因素分析中与较差总生存相关的因素包括年龄高于中位数(≥ 63岁)、Charlson-Deyo评分≥ 1、非学术/研究机构、低分化/未分化分级、切缘阳性及淋巴结阳性。
  • 与术后化疗相比,围手术期化疗和术后放化疗均与生存改善相关(HR 0.78和0.79;p < 0.001)。
  • 与围手术期化疗相比,术后放化疗无显著差异(HR 1.01;p = 0.987)。
  • 上述结果在最佳治疗队列(n = 3418)中保持一致。

关键数值与推荐

  • 最佳治疗定义为诊断后45天内开始初始化疗、诊断后45天内切除、切缘阴性、切除后90天内辅助化疗及标准放疗剂量(45 Gy)。
  • 中位生存:围手术期化疗组60.6个月,术后放化疗组42.3个月,术后化疗组31.2个月。
  • 与术后化疗相比,围手术期化疗HR 0.78(p < 0.001),术后放化疗HR 0.79(p < 0.001)。
  • 与围手术期化疗相比,术后放化疗HR 1.01(p = 0.987)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multimodal treatment strategy including perioperative chemotherapy (PEC), postoperative chemoradiation therapy (POCR), and postoperative chemotherapy (POC) has been accepted as the standard of care in gastric cancer (GC). The ideal sequence and type of therapy remain undetermined. METHOD: The National Cancer Database was examined from 2006 to 2016 to identify patients with resectable non-cardia gastric cancer. Patient outcomes were compared based on the receipt of PEC, POCR, and POC. This comparison was repeated in a sub-group of patients who received optimal treatment. Optimal treatment was defined as initial chemotherapy within 45 days of diagnosis, resection within 45 days of diagnosis, negative margins, adjuvant chemotherapy within 90 days of resection and standard radiation dose (45 Gy). Kaplan-Meier test, log-rank test, and multivariable analysis (MVA) were performed. RESULTS: We identified 9589 patients. Median survival was greater in the PEC group followed by POCR and POC (60.6, 42.3, and 31.2 months, respectively). On MVA, factors associated with worse overall survival included age above median (≥ 63 years), Charlson-Deyo score of ≥ 1, non-academic/research program, poorly differentiated/undifferentiated grade, positive margins, and positive lymph nodes. Both PEC and POCR were associated with improved survival when compared to POC (HR 0.78 and 0.79; p < 0.001). When compared with PEC, no significant difference was noted with POCR (HR 1.01; p = 0.987). These results were maintained in optimally treated cohort (n = 3418). CONCLUSION: In patients with resectable non-cardia gastric cancer, both perioperative chemotherapy and postoperative chemoradiation therapy were associated with improved survival when compared to postoperative chemotherapy. No difference was noted between perioperative chemotherapy and postoperative chemoradiation therapy. These results were maintained in the optimally treated cohort.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Ajay PS, Rajamanickam RK, Rhee K, et al. Identifying the optimal treatment strategy in patients with resectable non-cardia gastric cancer. Surg Endosc. 2023. PMID: 37935921. doi:10.1007/s00464-023-10515-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。